Please login to the form below

Not currently logged in
Email:
Password:

3D printed epilepsy drug launched in the US

Aprecia’s Spritam is now available as a prescription drug
Spritam

The first ever drug manufactured using 3D printing technology is now available to US patients with epilepsy.

Aprecia Pharmaceutical's Spritam was approved by the FDA in August last year, with industry experts hailing it as the catalyst for a new era in drug development.

Spritam (levetiracetam) is an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in both adults and children aged four years and older with epilepsy.

The drug is created using a combination of 3D printing technology and formulation science - Aprecia's patented ZipDose technology - allowing the dosage to be easily tailored to each individual patient's requirements.

The treatment is designed to provide a new, “patient-friendly” option for those who find taking medication difficult.

A survey undertaken by Hermes Pharma in 2014 found that 40-50% of participants have experienced difficulty swallowing tablets and capsules, with 8% admitting to skipping doses as a result.

The 3D printing of Spritam enables it to be produced as a porous formulation that rapidly disintegrates with a sip of liquid - even at high doses.

Don Wetherhold, chief executive of Aprecia, said: “Spritam is designed to transform what it is like to take epilepsy medication, and is the first in a line of products we are developing to provide patients and their caregivers with additional treatment options.”

Aprecia will primarily focus its ZipDose technology on the central nervous system therapeutic area where there is a real need for medicines that are easy to take, it said in a statement.

Nearly three million people live with epilepsy in the US, with approximately 150,000 new cases being diagnosed every year.

Article by
Rebecca Clifford

24th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Understanding the chronic disease patient journey in emerging markets
...
Infographic: Keeping tracking on track
Our best practice approach to tracking studies....
What does the Five Year Forward View mean for pharma?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services....

Infographics